were biopsy naive and 145 (31%) had at least one prior negative prostate biopsy. MpMRI-TRUS-fusion guided template prostate biopsy detected csPCa in 193 (41%) patients. All mpMRI-RCs clearly outperform the established mpMRI-naive RCs, when it comes to discrimination (RC1: 0.73, RC2: 0.84, RC3: 0.83, PCBG: 0.68, PCPT2: 0.66). Calibration of RC2, PBCG and PCPT2 were considerably worse compared to RC1 and RC3 (predicted proportion of csPCa were 0.43, 0.68, 0.39, 0.29 and 0.12 for RC1, RC2, RC3, PBCG and PCPT2 respectively. RC3 added an incremental benefit over the other PC-RCs in a decision curve analysis across the range of clinically meaningful threshold probabilities to biopsy.
INTRODUCTION AND OBJECTIVES:
With the increasing recognition of the over-diagnosis and over-treatment of prostate cancer (PCa), the choice of a better prostate biopsy strategy had confused both the patients and clinical surgeons. Hence, this network meta-analysis was conducted to clarify this question.
METHODS: In the current network meta-analysis, twenty eligible randomized controlled trials (RCTs) with 4,571 participants were comprehensively identified through Pubmed, Embase and Web of Science databases up to July 2017. The pooled odds ratio (OR) with 95% credible interval (CrI) was calculated by Markov chain Monte Carlo methods. A Bayesian network meta-analysis was conducted by using R-3.4.0 software with the help of package "gemtc" version 0.8.2.
RESULTS: Six different PCa biopsy strategies and four clinical outcomes were ultimately analyzed in this study. Although, the efficacy of different PCa biopsy strategies by ORs with corresponding 95% CrIs had not yet reached statistical differences, the cumulative rank probability indicated that overall PCa detection rate from best to worst was FUS-GB plus TRUS-GB, FUS-GB, CEUS, MRI-GB, TRUS-GB and TPUS-GB. In terms of clinically significant PCa detection, CEUS, FUS-GB or FUS-GB plus TRUS-GB had a higher, whereas TRUS-GB or TPUS-GB had a relatively lower significant detection rate. Meanwhile, TPUS-GB or TRUS-GB had a higher insignificant PCa detection rate. As for TRUS-guided biopsy, the general trend was that the more biopsy cores, the higher overall PCa detection rate. As for targeted biopsy, it could yield a comparable or even a better effect with fewer cores, compared with traditional random biopsy.
CONCLUSIONS: Taken together, in a comprehensive consideration of four clinical outcomes, our outcomes shed light on that FUS-GB or FUS-GB plus TRUS-GB showed their superiority, compared with other puncture methods in the detection of PCa. Moreover, TPUS or TRUS-GB was more easily associated with the over-diagnosis and over-treatment of PCa. In addition, targeted biopsy was obviously more effective than traditional random biopsy. The subsequent RCTs with larger sample sizes were required to validate our findings. (Recommended 53.2%; n[107, For consideration 20.4%; n[41) . Prostate cancer treatments were varied by age and stage. Especially, patients with 75 years and older age and stage IIA, IV groups were less likely to be less concordant than other stage and age groups. Logistic regression analysis revealed ECOG PS !1 and 75 years and older age were significantly less likely to be concordant (p[0.001 and p[0.026, respectively).
CONCLUSIONS: The treatment recommendations by WFO and actual patient received treatment showed relatively high concordance rate in the prostate cancer patients. Lowering concordance rate of prostate cancer treatment was seemed to be affected by higher performance status, older age, and advanced cancer stage.
Source of Funding: none

MP18-14 SIMULATED RESULTS OF THE PRECISION ALGORITHM FOR PROSTATE CANCER DIAGNOSIS AT A SINGLE ACADEMIC CENTER: SAFETY AND RISK FACTORS FOR FAILURE
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INTRODUCTION AND OBJECTIVES:
The PRECISION trial recently demonstrated the superiority of a novel algorithm over traditional systematic biopsy for the detection of clinically significant (CS) prostate cancer in biopsy-naive men. In this algorithm, all men with clinically suspected disease undergo prostate MRI followed by MRI fusion biopsy (MRF) if a lesion is detected. Systematic biopsy is omitted entirely. Concerns remain regarding the safety this algorithm, especially at centers inexperienced with MRF.
METHODS: We retrospectively reviewed all biopsy-naive men who underwent prostate MRI followed by 12-core sextant biopsy following initiation of an MRF program at our institution. All men with a PIRADS 3 or greater lesion also underwent concurrent software-assisted MRF biopsy. The proportion of men who would have been diagnosed with CS (Gleason score !3þ4) disease by the PRECISION algorithm was compared to systematic biopsy alone. Characteristics of men diagnosed with CS disease on systematic biopsy but not the PRECISION algorithm (PRECISION failures) were examined.
